| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Daniel J Lodge | |
| Stephanie M Perez | |||
| P2860 | cites work | Increased synaptic dopamine function in associative regions of the striatum in schizophrenia | Q43145582 |
| Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat. | Q43185402 | ||
| Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. | Q43653441 | ||
| Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less | Q43654303 | ||
| Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. | Q44050068 | ||
| Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins | Q44174112 | ||
| Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers | Q44201512 | ||
| Receptor activity and turnover of dopamine and noradrenaline after neuroleptics | Q44220849 | ||
| A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology | Q21245281 | ||
| The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 | ||
| Benzodiazepines for schizophrenia | Q24246319 | ||
| Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology | Q24306621 | ||
| Neuregulin 1 and susceptibility to schizophrenia | Q24616921 | ||
| GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia | Q24642711 | ||
| Forebrain and midbrain distribution of major benzodiazepine-sensitive GABAA receptor subunits in the adult C57 mouse as assessed with in situ hybridization | Q24656199 | ||
| Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia | Q26822851 | ||
| Disruption of two novel genes by a translocation co-segregating with schizophrenia | Q28144559 | ||
| A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia | Q37369353 | ||
| Second-generation antipsychotics for schizophrenia: can we resolve the conflict? | Q37428125 | ||
| Review: The biological basis of antipsychotic response in schizophrenia | Q37638930 | ||
| The genetics of schizophrenia. Current knowledge and future directions | Q37732153 | ||
| After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. | Q37834132 | ||
| Cortical basket cell dysfunction in schizophrenia | Q37973314 | ||
| Genomic copy number variations: A breakthrough in our knowledge on schizophrenia etiology? | Q38010589 | ||
| Twin studies of psychiatric illness. Current status and future directions | Q40769310 | ||
| Which GABAA-receptor subtypes really occur in the brain? | Q41003268 | ||
| Evaluation of treatment-resistant schizophrenia | Q41640700 | ||
| Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons | Q41827725 | ||
| Analysis of the DISC1 translocation partner (11q14.3) in genetic risk of schizophrenia | Q42253625 | ||
| Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. | Q42519170 | ||
| The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. | Q42545356 | ||
| Deep brain stimulation in patients with refractory temporal lobe epilepsy | Q42630088 | ||
| Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects | Q28146257 | ||
| Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies | Q28190066 | ||
| Genes for schizophrenia? Recent findings and their pathophysiological implications | Q28207952 | ||
| Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus | Q28241545 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats | Q28280906 | ||
| Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis | Q28293647 | ||
| Mice with reduced NMDA receptor expression display behaviors related to schizophrenia | Q28510751 | ||
| Expression of alpha 5 GABAA receptor subunit in developing rat hippocampus | Q28566832 | ||
| Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort | Q28943470 | ||
| Cortical inhibitory neurons and schizophrenia | Q29547683 | ||
| Deep brain stimulation for treatment-resistant depression | Q29616769 | ||
| Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence | Q29618819 | ||
| Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses | Q29618915 | ||
| Recent advances in the phencyclidine model of schizophrenia | Q29618917 | ||
| A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia | Q30465716 | ||
| Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia | Q30478274 | ||
| Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia | Q30540732 | ||
| The neuropathology of schizophrenia. A critical review of the data and their interpretation | Q30573678 | ||
| Do we still believe in the dopamine hypothesis? New data bring new evidence | Q30906669 | ||
| Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors | Q31970074 | ||
| The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia | Q33537860 | ||
| Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders | Q33555684 | ||
| Hippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophrenia | Q33637819 | ||
| Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data | Q33640930 | ||
| The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis | Q33693510 | ||
| The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia | Q33693516 | ||
| Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies | Q33833648 | ||
| GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder | Q33948632 | ||
| Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia | Q33957624 | ||
| Atypical antipsychotics: mechanism of action. | Q33957716 | ||
| Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review | Q33988376 | ||
| Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine | Q34048732 | ||
| Alterations of cortical GABA neurons and network oscillations in schizophrenia. | Q34058473 | ||
| Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs | Q34192438 | ||
| Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission | Q44536213 | ||
| Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients | Q44538137 | ||
| Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study | Q44752395 | ||
| Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. | Q44843756 | ||
| Postmortem evidence of structural brain changes in schizophrenia. Differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder | Q45297275 | ||
| Acute delta9-tetrahydrocannabinol-induced deficits in reversal learning: neural correlates of affective inflexibility | Q46423979 | ||
| Clozapine-induced tardive dyskinesia: a case report. | Q46468248 | ||
| The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation | Q46829207 | ||
| Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons | Q46866060 | ||
| Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. | Q46945434 | ||
| Fast-spiking non-pyramidal cells in the hippocampal CA3 region, dentate gyrus and subiculum of rats | Q48183670 | ||
| High frequency deep brain stimulation in the hippocampus modifies seizure characteristics in kindled rats | Q48230510 | ||
| Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia | Q48236425 | ||
| Impaired recruitment of the hippocampus during conscious recollection in schizophrenia | Q48242681 | ||
| Perseveration and strategy in a novel spatial self-ordered sequencing task for nonhuman primates: effects of excitotoxic lesions and dopamine depletions of the prefrontal cortex. | Q48320101 | ||
| Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia | Q48331829 | ||
| Reliability and state dependence of pyramidal cell-interneuron synapses in the hippocampus: an ensemble approach in the behaving rat. | Q48414964 | ||
| Phencyclidine-induced inhibition of rat prolactin secretion: increased portal blood dopamine | Q48506276 | ||
| Imaging D2 receptor occupancy by endogenous dopamine in humans | Q48632608 | ||
| An anatomy of schizophrenia? | Q48642309 | ||
| Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia | Q48685001 | ||
| Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex | Q48728126 | ||
| Intracellular and extracellular electrophysiology of nigral dopaminergic neurons--1. Identification and characterization | Q48730022 | ||
| Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. | Q49128057 | ||
| The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. | Q50872235 | ||
| Clozapine-related tardive dyskinesia. | Q52025914 | ||
| Use of chlorpromazine and reserpine in mental disorders. | Q52169834 | ||
| Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. | Q52542401 | ||
| DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population. | Q53239856 | ||
| Genetic basis of schizophrenia | Q55064430 | ||
| Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample | Q57016397 | ||
| A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia | Q61713924 | ||
| Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotypes behavior and ataxia in rats | Q67020057 | ||
| Schizophrenia | Q72240986 | ||
| Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine | Q73196289 | ||
| Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans | Q73390758 | ||
| Dimensions of psychosis in affected sibling pairs | Q73431004 | ||
| Network interactions in schizophrenia - therapeutic implications | Q73553195 | ||
| Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. | Q34214883 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects | Q34315836 | ||
| Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs | Q34338202 | ||
| Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies | Q34346365 | ||
| Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. | Q34353712 | ||
| Management of negative symptoms of schizophrenia | Q34370981 | ||
| [3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the alpha 5 subunit | Q34414902 | ||
| Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient | Q34463410 | ||
| History of the discovery and clinical introduction of chlorpromazine | Q34487502 | ||
| EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. | Q34540614 | ||
| The genetics of schizophrenia and bipolar disorder: dissecting psychosis | Q34555635 | ||
| Provocative tests with psychostimulant drugs in schizophrenia | Q34559517 | ||
| Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). | Q34570934 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance | Q34640811 | ||
| Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia | Q34661211 | ||
| Lamina- and cell-specific alterations in cortical somatostatin receptor 2 mRNA expression in schizophrenia | Q34987919 | ||
| A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia | Q35158189 | ||
| Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia | Q35175354 | ||
| Schizophrenia: family studies and treatment of spectrum disorders | Q35236290 | ||
| The epidemology of schizophrenia: replacing dogma with knowledge | Q35237282 | ||
| The significance of age of onset for schizophrenia | Q35325646 | ||
| Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator | Q35760205 | ||
| Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies | Q36005352 | ||
| A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia | Q36070114 | ||
| NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia | Q36245009 | ||
| Aberrant dopamine D2-like receptor function in a rodent model of schizophrenia | Q36335503 | ||
| The dopamine transporter: a vigilant border control for psychostimulant action | Q36487958 | ||
| Obsessive-compulsive disorder: recognition across medical settings, and treatments from behavior therapy to neurosurgery. | Q36501482 | ||
| Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: implications for schizophrenia | Q36501678 | ||
| A loss of hippocampal perineuronal nets produces deficits in dopamine system function: relevance to the positive symptoms of schizophrenia | Q36593850 | ||
| The neuropathology of schizophrenia: past and present. | Q36754511 | ||
| Regulation of firing of dopaminergic neurons and control of goal-directed behaviors | Q36776758 | ||
| The nature of dopamine dysfunction in schizophrenia and what this means for treatment | Q37062793 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| amine | Q167198 | ||
| dopamine | Q170304 | ||
| antipsychotics | Q208144 | ||
| phenol | Q407142 | ||
| hydrocarbon | Q43648 | ||
| P304 | page(s) | 887-896 | |
| P577 | publication date | 2014-07-02 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways | |
| P478 | volume | 8 |
| Q27693854 | Cerebral Toxocariasis: Silent Progression to Neurodegenerative Disorders? |
| Q50593929 | Clinical Management of Antipsychotic-Induced Hyperprolactinemia. |
| Q57792611 | Convergent inputs from the hippocampus and thalamus to the nucleus accumbens regulate dopamine neuron activity |
| Q47911078 | Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity |
| Q64258877 | Distinct Time-Course of Alterations of Groups I and II Metabotropic Glutamate Receptor and GABAergic Receptor Expression Along the Dorsoventral Hippocampal Axis in an Animal Model of Psychosis |
| Q35575042 | Focus on psychosis |
| Q26798948 | Functional alterations of astrocytes in mental disorders: pharmacological significance as a drug target |
| Q58701316 | Optogenetic induction of the schizophrenia-related endophenotype of ventral hippocampal hyperactivity causes rodent correlates of positive and cognitive symptoms |
| Q41047079 | The antipsychotic drugs olanzapine and haloperidol modify network connectivity and spontaneous activity of neural networks in vitro |
| Q90314548 | Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat |
Search more.